Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics
Open Access
- 18 November 2019
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-12
Abstract
A better understanding of the molecular mechanisms that participate in the development and clinical manifestations of schizophrenia can lead to improve our ability to diagnose and treat this disease. Previous data strongly associated the levels of deregulated ADAMTS2 expression in peripheral blood mononuclear cells (PBMCs) from patients at first episode of psychosis (up) as well as in clinical responders to treatment with antipsychotic drugs (down). In this current work, we performed an independent validation of such data and studied the mechanisms implicated in the control of ADAMTS2 gene expression. Using a new cohort of drug-naïve schizophrenia patients with clinical follow-up, we confirmed that the expression of ADAMTS2 was highly upregulated in PBMCs at the onset (drug-naïve patients) and downregulated, in clinical responders, after treatment with antipsychotics. Mechanistically, ADAMTS2 expression was activated by dopaminergic signalling (D1-class receptors) and downstream by cAMP/CREB and mitogen-activated protein kinase (MAPK)/ERK signalling. Incubation with antipsychotic drugs and selective PKA and MEK inhibitors abrogated D1-mediated activation of ADAMTS2 in neuronal-like cells. Thus, D1 receptors signalling towards CREB activation might participate in the onset and clinical responses to therapy in schizophrenia patients, by controlling ADAMTS2 expression and activity. The unbiased investigation of molecular mechanisms triggered by antipsychotic drugs may provide a new landscape of novel targets potentially associated with clinical efficacy.Keywords
Funding Information
- Ministerio de Economía y Competitividad (SAF2016-76046-R, SAF2013-46292-R, BES-2014-070615)
- LUCHAMOS POR LA VIDA project (Cantabria regional organization).
- Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (SAF2017-83702-R, Red TERCEL RD12/0019/0024)
- Generalitat Valenciana (GVA-PROMETEO 2018/041)
This publication has 48 references indexed in Scilit:
- Extracellular matrix abnormalities in schizophreniaNeuropharmacology, 2012
- Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?Therapeutic Advances in Psychopharmacology, 2011
- Role of beta-arrestin 2 downstream of dopamine receptors in the basal gangliaFrontiers in Neuroanatomy, 2011
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Epidemiological factors associated with treated incidence of first‐episode non‐affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of PsychosisEarly Intervention in Psychiatry, 2008
- Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolarsProceedings of the National Academy of Sciences, 2007
- Domains and Maturation Processes That Regulate the Activity of ADAMTS-2, a Metalloproteinase Cleaving the Aminopropeptide of Fibrillar Procollagens Types I–III and VJournal of Biological Chemistry, 2005
- The many faces of CREBTrends in Neurosciences, 2005
- Structure of the adenylyl cyclase catalytic coreNature, 1997
- Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: A horseradish peroxidase study in the ratJournal of Comparative Neurology, 1979